Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
15.02
-0.98 (-6.16%)
At close: Apr 2, 2026, 4:00 PM EDT
15.10
+0.08 (0.57%)
After-hours: Apr 2, 2026, 7:58 PM EDT
Tenax Therapeutics Employees
As of December 31, 2025, Tenax Therapeutics had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change (1Y)
10
Growth (1Y)
166.67%
Revenue / Employee
n/a
Profits / Employee
-$3,287,438
Market Cap
755.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 10 | 166.67% | 14 | 2 |
| Dec 31, 2024 | 6 | 0 | - | 4 | 2 |
| Dec 31, 2023 | 6 | -2 | -25.00% | 5 | 1 |
| Dec 31, 2022 | 8 | -1 | -11.11% | 7 | 1 |
| Dec 31, 2021 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| ARS Pharmaceuticals | 163 |
| Sana Biotechnology | 142 |
| Cullinan Therapeutics | 109 |
| ORIC Pharmaceuticals | 104 |
| Theravance Biopharma | 90 |
| Alto Neuroscience | 68 |
| Jade Biosciences | 55 |
TENX News
- 24 days ago - Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Tenax Therapeutics: A Speculative Buy - Seeking Alpha
- 3 months ago - Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
- 3 months ago - Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewsWire
- 4 months ago - Tenax Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript - Seeking Alpha